k8凯发(中国)天生赢家·一触即发

IMPACT Therapeutics announced today that the Ph I clinical trial data of its Wee 1 inhibitor IMP7068 trial was presented at 2022 ESMO congress held from Sep 9 to 13, 2022 in Paris, France. The poster presented the preliminary safety, pharmacokinetic, and pharmacodynamic profiles of the IMP7068 in patients with advanced solid tumors.  (Refer to ESMO2022 for more details).

Highlights of the poster (refer to ESMO Congress 2022 for more details):

Poster ID: 482P

Title: Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors

Time & locations: 12 September 2022 (CEST) & hall 4

About IMP7068

IMP7068 is a potent and selective WEE1 inhibitor. The preliminary result of the safety, tolerability, pharmacokinetic, pharmacodynamic profiles and antitumor activity of IMP7068 in patients with advanced solid tumors in the monotherapy dose escalation part of the study was presented. Thirty-two patients were enrolled in eight dose cohorts. Median follow-up duration was 212 days, and one patient (uterine serous carcinoma) had a best overall response of partial response. The rate of treatment-related adverse event (TRAE) was 65.6%, and TRAEs were mostly grade 1–2. IMP7068 was well-tolerated, and its PK and PD profiles were consistent with WEE1 inhibition and were dose dependent.

About IMPACT Therapeutics

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received US IND Clearance from FDA and China IND application from NMPA and the first patient has been dosed in the US. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA.